Found: 34
Select item for more details and to access through your institution.
Hybrid simultaneous whole-body 2-[<sup>18</sup>F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results.
- Published in:
- European Radiology, 2023, v. 33, n. 9, p. 6438, doi. 10.1007/s00330-023-09593-1
- By:
- Publication type:
- Article
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 15, p. 5406, doi. 10.3390/ijms21155406
- By:
- Publication type:
- Article
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 10, p. 2564, doi. 10.3390/ijms20102564
- By:
- Publication type:
- Article
PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 2, p. 445, doi. 10.3390/ijms18020445
- By:
- Publication type:
- Article
Immuno-PET for Clinical Theranostic Approaches.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 1, p. 57, doi. 10.3390/ijms18010057
- By:
- Publication type:
- Article
Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?
- Published in:
- Current Oncology, 2024, v. 31, n. 6, p. 3199, doi. 10.3390/curroncol31060242
- By:
- Publication type:
- Article
Prognostic Value of <sup>18</sup>F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 1, p. 156, doi. 10.2967/jnumed.123.265872
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 257, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 4, p. 947, doi. 10.1007/s00259-023-06568-8
- By:
- Publication type:
- Article
Pretargeting for imaging and therapy in oncological nuclear medicine.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2017, v. 2, n. 1, p. 1, doi. 10.1186/s41181-017-0026-8
- By:
- Publication type:
- Article
Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis.
- Published in:
- International Journal of Computer Assisted Radiology & Surgery, 2020, v. 15, n. 1, p. 129, doi. 10.1007/s11548-019-02015-y
- By:
- Publication type:
- Article
Traitements locorégionaux du cholangiocarcinome intra-hépatique.
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2023, v. 30, n. 5, p. 475, doi. 10.1684/hpg.2023.2591
- By:
- Publication type:
- Article
Place de la médecine nuclé aire dans la prise en charge des tumeurs neuroendocrines digestives.
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2017, v. 24, n. 1, p. 26, doi. 10.1684/hpg.2016.1397
- By:
- Publication type:
- Article
Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 4, p. 1005, doi. 10.1007/s00259-020-05049-6
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT in multiple myeloma: critical insights and future directions.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
ImmunoPET to help stratify patients for targeted therapies and to improve drug development.
- Published in:
- 2016
- By:
- Publication type:
- Editorial
Chirurgie bariatrique et fertilité masculine.
- Published in:
- Médecine de la Reproduction, 2020, v. 22, n. 1, p. 24, doi. 10.1684/mte.2020.0788
- By:
- Publication type:
- Article
Value of FDG-PET/CT in monitoring cyst infections in patients with autosomal dominant polycystic renal disease.
- Published in:
- Clinical Kidney Journal, 2021, v. 14, n. 10, p. 2273, doi. 10.1093/ckj/sfab077
- By:
- Publication type:
- Article
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2721, doi. 10.3390/cancers12092721
- By:
- Publication type:
- Article
Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2532, doi. 10.3390/cancers12092532
- By:
- Publication type:
- Article
ImmunoPET in Multiple Myeloma—What? So What? Now What?
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1467, doi. 10.3390/cancers12061467
- By:
- Publication type:
- Article
FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1384, doi. 10.3390/cancers12061384
- By:
- Publication type:
- Article
Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 2, p. 486, doi. 10.3390/cancers12020486
- By:
- Publication type:
- Article
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.
- Published in:
- Cancers, 2019, v. 11, n. 9, p. 1282, doi. 10.3390/cancers11091282
- By:
- Publication type:
- Article
Prognostic value of FDG‐PET/CT response for patient selection before chimeric antigen receptor‐T‐cells therapy in non‐Hodgkin lymphoma.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 4, p. 796, doi. 10.1002/hon.2965
- By:
- Publication type:
- Article
Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45215-y
- By:
- Publication type:
- Article
Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45215-y
- By:
- Publication type:
- Article
Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.
- Published in:
- PLoS ONE, 2016, v. 11, n. 7, p. 1, doi. 10.1371/journal.pone.0159984
- By:
- Publication type:
- Article